Impel NeuroPharma Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Impel NeuroPharma Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10620
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Impel NeuroPharma Inc (Impel) is a clinical-stage biotechnology company that which develops intranasal drug treatments for central nervous system disorders. The company’s product pipeline includes INP104, INP103, INP102, INP101, INP105, and INP106. It also develops Precision Olfactory Delivery technology, a nasal drug delivery platform that delivers drugs for improved biodistribution. Impel’s products are used for the treatment of pain, depression, bipolar disorder, Alzheimer’s disease, migraine and Parkinson’s disease, among others. The company serves pharmaceutical and biotechnology companies, and premier academic research institutions. Impel is headquartered in Seattle, Washington, the US.

Impel NeuroPharma Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Impel NeuroPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 11
Impel NeuroPharma Raises USD22.3 Million in Venture Financing 12
Impel NeuroPharma Raises USD0.08 Million in Venture Financing 13
Impel Neuropharma Raises US$2.6 Million In Venture Financing 14
Partnerships 15
Impel NeuroPharma and Camargo Pharma Enter into Agreement 15
3M Drug Delivery Systems Enters into Agreement with Impel NeuroPharma 16
Licensing Agreements 17
Centre for Addiction and Mental Health Enters into Licensing Agreement with Impel NeuroPharma 17
Impel NeuroPharma Inc – Key Competitors 18
Impel NeuroPharma Inc – Key Employees 19
Impel NeuroPharma Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Corporate Communications 21
Nov 07, 2018: Impel NeuroPharma names Ellen A. Lubman as chief business officer 21
Oct 03, 2017: Impel NeuroPharma Board Announces Appointment of Jon Congleton as CEO 22
Mar 03, 2017: Veteran Biotech Executive Timothy S. Nelson Joins Impel’s Board of Directors 23
Clinical Trials 24
May 31, 2018: Impel NeuroPharma Announces Initiation of Phase IIa Study of INP103 in Parkinson’s Disease OFF Episodes 24
Feb 07, 2018: Impel NeuroPharma Announces Positive Results of Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache 25
Oct 31, 2017: Impel NeuroPharma Announces First Patient Dosed in Phase 1 Clinical Trial of INP104 for Treatment of Acute Migraine Headache 26
Other Significant Developments 27
Feb 07, 2017: Impel NeuroPharma Partners with Camargo Pharmaceutical Services for Development Programs 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Key Facts 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Impel NeuroPharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Impel NeuroPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Impel NeuroPharma Raises USD21 Million in First Tranche of Series C Financing 11
Impel NeuroPharma Raises USD22.3 Million in Venture Financing 12
Impel NeuroPharma Raises USD0.08 Million in Venture Financing 13
Impel Neuropharma Raises US$2.6 Million In Venture Financing 14
Impel NeuroPharma and Camargo Pharma Enter into Agreement 15
3M Drug Delivery Systems Enters into Agreement with Impel NeuroPharma 16
Centre for Addiction and Mental Health Enters into Licensing Agreement with Impel NeuroPharma 17
Impel NeuroPharma Inc, Key Competitors 18
Impel NeuroPharma Inc, Key Employees 19

List of Figures
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Impel NeuroPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Impel NeuroPharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Impel NeuroPharma Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Personal Group Holdings Plc:企業の戦略・SWOT・財務情報
    Personal Group Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Personal Group Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NORDSEE GmbH.:企業の戦略・SWOT・財務情報
    NORDSEE GmbH. - Strategy, SWOT and Corporate Finance Report Summary NORDSEE GmbH. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • XALT Energy LLC:企業の戦略的SWOT分析
    XALT Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Protalix BioTherapeutics Inc (PLX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Taliglucerase (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients wi …
  • Industriens Pensionsforsikring AS:電力:M&Aディール及び事業提携情報
    Summary Industriens Pensionsforsikring AS (Industriens Pensionsforsikring) is an insurance service provider. The company offers member pension insurance and company pension insurance products. Its member pension insurance covers critical illness, loss of earning capacity, death, healthcare, insuranc …
  • Hotel Royal Limited:戦略・SWOT・企業財務分析
    Hotel Royal Limited - Strategy, SWOT and Corporate Finance Report Summary Hotel Royal Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Qiagen NV (QIA):企業の財務・戦略的SWOT分析
    Qiagen NV (QIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • AnaMar AB:製薬・医療:M&Aディール及び事業提携情報
    Summary AnaMar AB (AnaMar), a subsidiary of Koncentra Holding AB, is a drug discovery company that discovers, develops and commercializes therapeutic strategies to treat debilitating inflammation, fibrosis and pain. The company develops drug candidates from several chemical classes on the receptors …
  • Sunwin Stevia International Inc (SUWN):企業の財務・戦略的SWOT分析
    Sunwin Stevia International Inc (SUWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • TonenGeneral Sekiyu K.K. (5012)-石油・ガス分野:企業M&A・提携分析
    Summary TonenGeneral Sekiyu K.K. (TonenGeneral) is an energy company that imports, refines and processes crude oil. It also manufactures, distributes and markets petroleum and petrochemical products. The company’s product portfolio includes lubricants, naphtha, sulphur, kerosene, hydrocarbon resin, …
  • Danieli & C. Officine Meccaniche SpA:企業の戦略・SWOT・財務分析
    Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report Summary Danieli & C. Officine Meccaniche SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • AGCO Corporation (AGCO):企業の財務・戦略的SWOT分析
    AGCO Corporation (AGCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Taiheiyo Cement Corporation:企業の戦略・SWOT・財務分析
    Taiheiyo Cement Corporation - Strategy, SWOT and Corporate Finance Report Summary Taiheiyo Cement Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Sonatrach SPA-石油・ガス分野:企業M&A・提携分析
    Summary Sonatrach SPA (Sonatrach) is a state-owned integrated oil and gas company. Its businesses include exploration and production; pipeline transportation; liquefaction, refining and petrochemicals; marketing of petroleum products; maritime transportation; and other services. The company explores …
  • Perficient Inc (PRFT):企業の財務・戦略的SWOT分析
    Perficient Inc (PRFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Meritage Homes Corporation:企業の戦略・SWOT・財務情報
    Meritage Homes Corporation - Strategy, SWOT and Corporate Finance Report Summary Meritage Homes Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Golar LNG Ltd (GOL):石油・ガス:M&Aディール及び事業提携情報
    Summary Golar LNG Limited (Golar LNG) is a midstream liquefied natural gas (LNG) company. It provides liquefaction, transport, storage, and re-gasification services to customers in the LNG industry. The company owns and operates LNG carriers and FSRUs; and develops FLNGVs. Through a joint venture wi …
  • Claret Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Claret Medical Inc (Claret Medical), a subsidiary of Boston Scientific Corp develops and commercializes cerebral protection systems. The company offers medical devices for cerebral protection during structural heart and vascular interventions, and cardiac surgery procedures. Its lead product …
  • Biohaven Pharmaceutical Holding Company Ltd (BHVN):製薬・医療:M&Aディール及び事業提携情報
    Summary Biohaven Pharmaceutical Holding Company Ltd (Biohaven), a subsidiary of Portage Biotech Inc, is a clinical-stage biopharmaceutical company that develops late-stage product candidates for neurological diseases. The company develops small molecule CGRP receptor antagonist platform that include …
  • Atomenergoprom:企業の戦略的SWOT分析
    Atomenergoprom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆